Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. 2017

Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
Department of Clinical Chemistry and Toxicology, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Brazil.

Oxcarbazepine is indicated for the treatment of partial or generalised tonic-clonic seizures. Most of the absorbed oxcarbazepine is converted into its active metabolite, 10-hydroxycarbazepine (MHD), which can exist as R-(-)- and S-(+)-MHD enantiomers. Here we describe the influence of the P-glycoprotein (P-gp) inhibitor verapamil, on the disposition of oxcarbazepine and MHD enantiomers, both of which are P-gp substrates. Healthy subjects (n=12) were randomised to oxcarbazepine or oxcarbazepine combined with verapamil at doses of 300mg b.i.d. and 80mg t.i.d., respectively. Blood samples (n=185) were collected over a period of 12h post oxcarbazepine dose. An integrated PK model was developed using nonlinear mixed effects modelling using a meta-analytical approach. The pharmacokinetics of oxcarbazepine was described by a two-compartment model with absorption transit compartments and first-order elimination. The concentration-time profiles of both MHD enantiomers were characterised by a one-compartment distribution model. Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers. The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively). Co-administration of verapamil resulted in a modest increase of the apparent bioavailability of oxcarbazepine by 12% (10-28), but did not affect parent or metabolite clearances. Despite the evidence of comparable systemic levels of OXC and MHD following administration of verapamil, differences in brain exposure to both moieties cannot be excluded after P-glycoprotein inhibition.

UI MeSH Term Description Entries
D008297 Male Males
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078330 Oxcarbazepine A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4. 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide,GP 47680,Timox,Trileptal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012640 Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or "seizure disorder." Absence Seizure,Absence Seizures,Atonic Absence Seizure,Atonic Seizure,Clonic Seizure,Complex Partial Seizure,Convulsion,Convulsions,Convulsive Seizure,Convulsive Seizures,Epileptic Seizure,Epileptic Seizures,Generalized Absence Seizure,Generalized Tonic-Clonic Seizures,Jacksonian Seizure,Myoclonic Seizure,Non-Epileptic Seizure,Nonepileptic Seizure,Partial Seizure,Seizure,Seizures, Convulsive,Seizures, Focal,Seizures, Generalized,Seizures, Motor,Seizures, Sensory,Tonic Clonic Seizure,Tonic Seizure,Tonic-Clonic Seizure,Atonic Absence Seizures,Atonic Seizures,Clonic Seizures,Complex Partial Seizures,Convulsion, Non-Epileptic,Generalized Absence Seizures,Myoclonic Seizures,Non-Epileptic Seizures,Nonepileptic Seizures,Partial Seizures,Petit Mal Convulsion,Seizures, Auditory,Seizures, Clonic,Seizures, Epileptic,Seizures, Gustatory,Seizures, Olfactory,Seizures, Somatosensory,Seizures, Tonic,Seizures, Tonic-Clonic,Seizures, Vertiginous,Seizures, Vestibular,Seizures, Visual,Single Seizure,Tonic Seizures,Tonic-Clonic Seizures,Absence Seizure, Atonic,Absence Seizure, Generalized,Absence Seizures, Atonic,Absence Seizures, Generalized,Auditory Seizure,Auditory Seizures,Clonic Seizure, Tonic,Clonic Seizures, Tonic,Convulsion, Non Epileptic,Convulsion, Petit Mal,Convulsions, Non-Epileptic,Focal Seizure,Focal Seizures,Generalized Seizure,Generalized Seizures,Generalized Tonic Clonic Seizures,Generalized Tonic-Clonic Seizure,Gustatory Seizure,Gustatory Seizures,Motor Seizure,Motor Seizures,Non Epileptic Seizure,Non Epileptic Seizures,Non-Epileptic Convulsion,Non-Epileptic Convulsions,Olfactory Seizure,Olfactory Seizures,Partial Seizure, Complex,Partial Seizures, Complex,Seizure, Absence,Seizure, Atonic,Seizure, Atonic Absence,Seizure, Auditory,Seizure, Clonic,Seizure, Complex Partial,Seizure, Convulsive,Seizure, Epileptic,Seizure, Focal,Seizure, Generalized,Seizure, Generalized Absence,Seizure, Generalized Tonic-Clonic,Seizure, Gustatory,Seizure, Jacksonian,Seizure, Motor,Seizure, Myoclonic,Seizure, Non-Epileptic,Seizure, Nonepileptic,Seizure, Olfactory,Seizure, Partial,Seizure, Sensory,Seizure, Single,Seizure, Somatosensory,Seizure, Tonic,Seizure, Tonic Clonic,Seizure, Tonic-Clonic,Seizure, Vertiginous,Seizure, Vestibular,Seizure, Visual,Seizures, Generalized Tonic-Clonic,Seizures, Nonepileptic,Sensory Seizure,Sensory Seizures,Single Seizures,Somatosensory Seizure,Somatosensory Seizures,Tonic Clonic Seizures,Tonic-Clonic Seizure, Generalized,Tonic-Clonic Seizures, Generalized,Vertiginous Seizure,Vertiginous Seizures,Vestibular Seizure,Vestibular Seizures,Visual Seizure,Visual Seizures
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer

Related Publications

Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
December 1999, Clinical pharmacology and therapeutics,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
January 1990, European journal of clinical pharmacology,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
October 1993, British journal of clinical pharmacology,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
January 1989, European journal of clinical pharmacology,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
February 2016, European journal of clinical pharmacology,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
July 2022, British journal of clinical pharmacology,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
June 1990, Journal of chromatography,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
June 2005, Journal of clinical pharmacology,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
October 2015, International journal of clinical pharmacology and therapeutics,
Natalicia de Jesus Antunes, and Sven C van Dijkman, and Vera Lucia Lanchote, and Lauro Wichert-Ana, and Eduardo Barbosa Coelho, and Veriano Alexandre Junior, and Osvaldo Massaiti Takayanagui, and Eduardo Tozatto, and J G Coen van Hasselt, and Oscar Della Pasqua
July 2002, Journal of mass spectrometry : JMS,
Copied contents to your clipboard!